Benefits of Continuous Subcutaneous Insulin Infusion (CSII) Therapy in Preschool Children

Abstract

Objective:

The incidence of type 1 diabetes mellitus (T1DM) in young children has increased considerably over recent years. The purpose was to examine the effectiveness and safety of continuous subcutaneous insulin infusion (CSII) therapy in preschool children with T1DM.

Methods:

A retrospective chart review of 113 children diagnosed with T1DM while younger than age 6 years. Mean age at diagnosis was 3.5±1.5 years and mean duration of follow 9.7±7.0 years. Patients were divided into 3 groups. Group1 initiated CSII therapy before the age of 6 years (n=26), Group 2 was treated with multiple daily injections (MDI) throughout follow-up (n=34), and Group 3 initiated CSII after age 6 (n=53). Metabolic control was assessed by HbA1C levels and safety by rates of severe hypoglycemia and diabetic ketoacidosis (DKA) events.

Results:

In Group 1, the highest mean HbA1C value (8.5%) was observed 1–2 years prior to CSII initiation. During the 5 year period following CSII initiation, mean HbA1C levels ranged between 7.4 and 8.0%. Throughout the entire follow-up period, mean HbA1C levels were lower for Group 1 than Group 2 (p=0.05). In Group 3, mean HbA1C level decreased from 8.7% pre-CSII to 8.3% post-CSII (p<0.001). Nevertheless HbA1C levels remained higher than for those who started pump therapy before age 6 (p=0.02).

Conclusions:

Our study demonstrated better metabolic control in pre-school children treated with CSII compared to those treated with MDI. This benefit sustained for 5 years after CSII initiation and was not accompanied by increased risk of severe hypoglycemia or DKA events.

Key words

type 1 diabetes - continuous subcutaneous insulin infusion - long term follow-up

• References

• 1 Patterson CC, Dahlquist GG, Gyurus E et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet 2009; 373: 2027-2033
• 2 Vehik K, Hamman RF, Lezotte D et al. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diabetes Care 2007; 30: 503-509
• 3 Ehehalt S, Neu A, Michaelis D et al. Incidence of type 1 diabetes in childhood before and after the reunification of Germany – an analysis of epidemiological data, 1960–2006. Exp Clin Endocrinol Diabetes 2012; 120: 441-444
• 4 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986
• 5 Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994; 125: 177-188
• 6 Cody D. Infant and toddler diabetes. Arch Dis Child 2007; 92: 716-719
• 7 Deiss D, Kordonouri O, Meyer K et al. Long hypoglycaemic periods detected by subcutaneous continuous glucose monitoring in toddlers and pre-school children with diabetes mellitus. Diabetic medicine: a journal of the British Diabetic Association 2001; 18: 337-338
• 8 Hannonen R, Komulainen J, Eklund K et al. Verbal and academic skills in children with early-onset type 1 diabetes. Dev Med Child Neurol 2010; 52: e143-e147
• 9 Tsalikian E, Fox L, Weinzimer S et al. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatric diabetes 2012; 13: 294-300
• 10 American Diabetes Association . Standards of medical care in diabetes – 2012. Diabetes Care 2012; 35 (Suppl. 01) S11-S63
• 11 Weinzimer SA, Swan KL, Sikes KA et al. Emerging evidence for the use of insulin pump therapy in infants, toddlers, and preschool-aged children with type 1 diabetes. Pediatr Diabetes 2006; 7 (Suppl. 04) 15-19
• 12 Ahern JA, Boland EA, Doane R et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 2002; 3: 10-15
• 13 Torres I, Ortego J, Valencia I et al. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues. Exp Clin Endocrinol Diabetes 2009; 117: 378-385
• 14 Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51: 941-951
• 15 Scrimgeour L, Cobry E, McFann K et al. Improved glycemic control after long-term insulin pump use in pediatric patients with type 1 diabetes. Diabetes Technol Ther 2007; 9: 421-428
• 16 Pankowska E, Blazik M, Dziechciarz P et al. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009; 10: 52-58
• 17 Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. J Pediatr Endocrinol Metab 2003; 16: 393-399
• 18 Berghaeuser MA, Kapellen T, Heidtmann B et al. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes 2008; 9: 590-595
• 19 Opipari-Arrigan L, Fredericks EM, Burkhart N et al. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes 2007; 8: 377-383
• 20 Eugster EA, Francis G. Position statement: Continuous subcutaneous insulin infusion in very young children with type 1 diabetes. Pediatrics 2006; 118: e1244-e1249
• 21 Pinhas-Hamiel O, Tzadok M, Hirsh G et al. The impact of baseline hemoglobin A1c levels prior to initiation of pump therapy on long-term metabolic control. Diabetes Technol Ther 2010; 12: 567-573
• 22 Litton J, Rice A, Friedman N et al. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002; 141: 490-495
• 23 Shehadeh N, Battelino T, Galatzer A et al. Insulin pump therapy for 1–6 year old children with type 1 diabetes. Isr Med Assoc J 2004; 6: 284-286
• 24 Bougneres PF, Landier F, Lemmel C et al. Insulin pump therapy in young children with type 1 diabetes. J Pediatr 1984; 105: 212-217
• 25 Weinzimer SA, Ahern JH, Doyle EA et al. Persistence of benefits of continuous subcutaneous insulin infusion in very young children with type 1 diabetes: a follow-up report. Pediatrics 2004; 114: 1601-1605
• 26 DiMeglio LA, Pottorff TM, Boyd SR et al. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr 2004; 145: 380-384
• 27 Wilson DM, Buckingham BA, Kunselman EL et al. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 2005; 28: 15-19
• 28 Fox LA, Buckloh LM, Smith SD et al. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005; 28: 1277-1281
• 29 Shalitin S, Phillip M. Which factors predict glycemic control in children diagnosed with type 1 diabetes before 6.5 years of age?. Acta Diabetol 2012; 49: 355-362
• 30 Ceriello A, Ihnat MA, Thorpe JE. Clinical review 2: The “metabolic memory”: is more than just tight glucose control necessary to prevent diabetic complications?. The Journal of clinical endocrinology and metabolism 2009; 94: 410-415
• 31 Ceriello A. Hypothesis: the “metabolic memory”, the new challenge of diabetes. Diabetes research and clinical practice 2009; 86 (Suppl. 01) S2-S6